U.S. Sunscreens Aren’t Great. The FDA Could Soon Change That

The FDA proposed allowing bemotrizinol, a broad-spectrum chemical UV filter used widely in Asia and Europe, to be sold over the counter in the U.S., with Commissioner Marty Makary acknowledging the agency has historically been slow and left Americans with fewer options. The move addresses a regulatory gap— the U.S. has only 16 approved UV filters versus more than 30 in Europe and the last U.S. approval was in 1999 — and bemotrizinol, approved in Europe in 2000, is shown to be safe, more long‑lasting, lighter and less greasy than many current ingredients. Approval could modernize the U.S. sunscreen market, broaden consumer choice, increase competition among manufacturers and potentially improve public-health outcomes through better sun protection.

Analysis

The FDA announced a proposal to permit bemotrizinol as an over-the-counter UV chemical filter in the U.S., with Commissioner Marty Makary acknowledging the agency has historically moved slowly; the article notes the U.S. currently approves 16 UV filters versus Europe’s more than 30 and that the last U.S. approval occurred in 1999, while bemotrizinol has been approved in Europe since 2000. Bemotrizinol provides broad-spectrum UVA and UVB protection, is described as lighter, longer-lasting and less greasy than many existing ingredients, and is already incorporated in popular sunscreens abroad, generating social-media-driven import demand among U.S. consumers. Industry implications include expanded product choice, potential reformulation and new product launches by sunscreen makers, and a likely boost to ingredient suppliers that can scale bemotrizinol production; the signals flag a mildly positive market impact (sentiment_score 0.28) and themes of regulation, healthcare and consumer demand. Key near-term risks are that the proposal is not a final rule, manufacturers will face reformulation and supply-chain lead times, and adoption and pricing dynamics will determine whether increased competition compresses margins or grows market share.

Key Decisions for Investors

• Investors should increase exposure to OTC sunscreen manufacturers and UV-filter ingredient suppliers with proven global R&D and manufacturing capabilities as approval could expand the addressable U.S. market
• Monitor the FDA rulemaking timeline and public comment process closely and avoid material position increases until final approval is confirmed given regulatory uncertainty
• Prioritize companies with existing bemotrizinol access or quick reformulation pathways because they are best positioned to capture early market share and avoid extended R&D expense
• Track consumer adoption indicators such as import/social-media trends, pricing responses and marketing rollouts to gauge demand elasticity and the potential for margin pressure from heightened competition